SAN

71.79

-2.25%↓

ARGX

795.6

+3.65%↑

SHL.DE

34.38

+0.73%↑

PHIA

23.72

+1.45%↑

FRE

39.3

-0.96%↓

SAN

71.79

-2.25%↓

ARGX

795.6

+3.65%↑

SHL.DE

34.38

+0.73%↑

PHIA

23.72

+1.45%↑

FRE

39.3

-0.96%↓

SAN

71.79

-2.25%↓

ARGX

795.6

+3.65%↑

SHL.DE

34.38

+0.73%↑

PHIA

23.72

+1.45%↑

FRE

39.3

-0.96%↓

SAN

71.79

-2.25%↓

ARGX

795.6

+3.65%↑

SHL.DE

34.38

+0.73%↑

PHIA

23.72

+1.45%↑

FRE

39.3

-0.96%↓

SAN

71.79

-2.25%↓

ARGX

795.6

+3.65%↑

SHL.DE

34.38

+0.73%↑

PHIA

23.72

+1.45%↑

FRE

39.3

-0.96%↓

Search

Pharming Group NV

Open

1.127

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.12

Max

1.1360000000000001

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-5.1M

Verkoop

-36M

71M

K/W

Sectorgemiddelde

55.5

49.712

EPS

-0.006

Winstmarge

-7.196

Werknemers

407

EBITDA

-4.8M

-2.1M

Dividenden

By Acuity

Volgende Winsten

30 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-225M

784M

Vorige openingsprijs

1.13

Vorige sluitingsprijs

1.127

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat